Customer Logins

Obtain the data you need to make the most informed decisions by accessing our extensive portfolio of information, analytics, and expertise. Sign in to the product or service center of your choice.

Customer Logins

World Markets Pricing and Reimbursement

Optimize your global pharmaceutical pricing, reimbursement and market access strategy.

World Markets Pricing & Reimbursement (WMPR) is a comprehensive analytical toolkit to understand the ever-shifting global market access and Pricing & Reimbursement (P&R) landscape. Includes daily analysis, hot topics, special reports, country profiles, detailed P&R data, as well as our International Reference Pricing (IRP) matrix, risk-sharing database and market access risk scores. Combine WMPR with our pharmaceutical and prescription drug price database, POLI, to get a complete picture of the future of pharma pricing and set your optimal strategy.

WMPR enables you to:

  • Understand key P&R drivers and costs within and across countries
  • Evolution of international reference pricing regulations​ 
  • Plan your launch-sequencing strategy based on international reference pricing rules and post-launch price adjustment dynamics
  • Anticipate price and reimbursement impact of regulatory changes
  • Learn evolving P&R requirements (clinical trial design, comparators, endpoints, cost, and more)
  • Monitor HTA evaluations process and risk sharing agreements in similar products
  • Find out payer cost-effectiveness evaluation process to shape your clinical program and reimbursement filing

What’s Included

Analysis

Headline Analysis
Daily review of global P&R policy changes, product-level P&R events, public and private health insurance reform and evolving HTA requirements

Special Reports
In-depth analysis of key P&R trends across major pharmaceutical markets. Selected by our analysts, based on recent market access trends, or recommended by clients

Hot Topics
Designed to provide insight into the latest pharmaceutical market access trends, the risks and opportunities for pharma companies. It includes our Market Access Month Ahead hot topic which provides an overview of critical P&R reforms, public consultations, and health technology assessment (HTA) decisions and publications that are planned within the next month

Country Profiles
In-depth profiles for 45 countries, covering:

  • Process for getting products reimbursed and priced
  • Overview of the pharmaceutical market's P&R structure and institutions
  • Specific cost containment analysis
  • Flow charts and policy comparisons
  • Policy change outlook
Data

International Reference Pricing (IRP) Matrix
Online tool to quickly compare almost 70 countries that use each other for referencing pricing plus a quarterly IRP bulletin of changes to IRP mechanisms around the world


Click to enlarge


Pricing and Reimbursement Policy Database
Interactive database of the major cost-containment policies across 70+ countries, including:

  • International reference pricing
  • Price cuts
  • Co-payments
  • HTA/Pharmaco-economic requirements
  • Generics substitution

Risk-sharing Agreement Database
Track, compare and analyze risk-sharing agreements – both performance and financially-based – around the world.

Market Access Risk Scores (MARS)

Quantitative platform assessing risk for access to innovative medicines in 70+ countries; provides overarching framework for our global P&R analysis. Fully consistent with all Economics & Country Risk ratings

Includes measures of:

  • Quantitative risk
  • Qualitative risk
  • Measures of stability
  • Event risk


Click to enlarge

Delivery Options

Connect®
Maximize your subscription content with IHS Markit Connect – our online customer platform. Connect is a one-stop solution for data searching and discovery, charting, downloading and saving for future use.

  • Explore market access risk via interactive heat maps and interactive tables
  • Understand P&R trends instantly with pricing indicators, visualized with dynamic charts
  • Save, reconfigure and export charts
  • Get a global P&R overview on the homepage
  • See all content and data for individual markets with country pages
  • Find and filter content
  • Generate your regular pdf and Word deliverables using Report Builder
  • Set up your preferred geographic regions
  • Precisely tailor email alerts
  • Data feed of IRP data into IRP simulation tools

REST API
Our API delivers data continuously and reliably directly into your workflow.

  • Representational State Transfer Application Programming (REST) API makes data available via URL addresses (or ‘endpoints’)
  • Provides a foundation on which to build databases, charts, websites, visualizations and CSV files, plus facilities to query and lookup specific data
  • Offers the simplest approach to application integration:
    • Access to the API is instantaneous
    • Provides an interactive web environment for developers to explore API features and review technical documentation
    • Developers can test the API calls interactively in a browser
  • 24/7 monitoring and support is provided
  • Scales horizontally for both datasets and clients, ensuring it can meet present and future demand
  • Built for consistent speed, with carefully selected technologies to ensure the best possible performance

IDDS
IDDS offers tailored data feeds featuring continuous updating and seamless delivery.

  • Internet Data Delivery System (IDDS) delivers fixed data updates in CSV or XML format to the IHS Markit web servers in real time
  • Metadata includes economic concept, geography, source and frequency
  • Updates pull in data changes only, optimizing load speed
  • Data updates can be scheduled

Solve Your Business Challenge

Challenge Solution Box
How can I assess the pricing and reimbursement landscape in a new target country? Review Country Profiles to get a clear, detailed view of a country’s pricing, including P&R, funding sources, regulatory and policy outlook, as well as our consolidated Market Access Risk Score (MARS) system.
How do I keep pace with P&R changes around the world, and what they mean for me? Get Daily Analysis on likely price shifts due to regulation, and view Country Reports for the latest P&R changes.
How can I find out when prices are re-evaluated in reference countries through international reference pricing? Use the International Reference Pricing (IRP) Matrix, Country Profiles and Daily Analysis to get real-time international price reference updates.
I need to identify reference countries and understand what my level of exposure to IRP risk is? Leverage the International Reference Pricing (IRP) Matrix to easily identify reference and referrer nations as well as the detailed IRP rules.
I struggle to get consistent information across markets. Rely on Country Profiles for consistent cross-country market analysis.
I need to understand how to design our clinical trial to secure market access around the world. Use our Daily Analysis to understand evolving requirements, and our Country Reports to understand existing standards.

Experts

Gustav Ando

Mr. Ando oversees the development of IHS Markit's global healthcare outlook analysis that focuses on market access, cost of healthcare and new treatment advances as well as coordinating its ongoing thinking on COVID-19. He heads the research and data teams that produce daily analysis, risk assessment and critical data for the pharmaceutical industry, as well as the consulting team that focuses on disease prevention, workforce and demand healthcare microsimulation models. With more than 15 years of experience in the industry, he is a regular speaker at conferences and is frequently cited by major media publications and national radio and television programs. He is the author and podium presenter of research at numerous academic conferences such as ISPOR. Mr Ando also oversees our global comparative industry group which provide critical long-term forecast perspectives across all industries around the world, as well as our specialised global constructrion group. Mr. Ando holds a postgraduate degree from the University of Uppsala, Sweden, and an undergraduate degree from the University of Durham in the United Kingdom.

View Profile

Milena Izmirlieva

Ms. Izmirlieva heads the Life Sciences research team which comprises senior analysts, analysts and health economists covering developed and emerging markets worldwide. Since joining IHS Markit's Global Insight in 2003 as a research analyst in the Pharma Practice for Western European and Central and Eastern European markets, she has developed extensive knowledge of the healthcare systems and pharmaceutical markets of numerous countries in Europe, North America and various emerging markets. Her main areas of research interest are pricing and reimbursement and market access for originator drugs, the market dynamics for biosimilars and generics, heath system efficiency indicators and health system capacity, and forecasting of healthcare spending and pharmaceutical sales. Before joining IHS Markit, she worked in healthcare marketing communications for the EURO RSCG group in New York, US, and Sofia, Bulgaria, where she specialised in pharmaceutical and medical device companies. She holds a Master of Science degree in Communication with a focus on Science Writing from Iowa State University and a joint BA degree in Journalism and Mass Communication and International Relations from the American University in Bulgaria, and is in the process of completing a Master of Science degree in Health Economics, Policy and Management at the London School of Economics. Ms. Izmirlieva is a regular speaker at pharmaceutical conferences and is often interviewed about pharmaceutical-related issues in the media. She frequently presents peer-reviewed research at ISPOR and has a strong interest in pharmaceutical pricing and reimbursement developments and cost-containment strategies (including international reference pricing). Ms. Izmirlieva is a Fulbright scholarship recipient and member of the following honour societies: Phi Kappa Phi, Alfa Delta Sigma, and Kappa Tau Alfa.​

View Profile

Cameron Lockwood

Mr. Lockwood collaborates with colleagues across Life Sciences and other teams to look at information and data rich solutions addressing client needs in the healthcare industry. Across diverse geographies, his work encompasses pricing and reimbursement, market access and policy-related topics relevant to pharmaceuticals, medical devices and other healthcare technologies. He oversees production of the “International Reference Pricing Guidebook,” IHS Markit’s comprehensive syndicated research offering detailing the nuances of IRP policy across 60+ countries. Cameron Lockwood joined the Life Sciences team in the London office in 2011, supporting the multiclient studies practice and he is currently based in the San Francisco Bay Area. Previously, he worked in the fields of healthcare communications and business intelligence. In addition to a graduate diploma in statistics through the University of Sheffield, he holds a Bachelor of Science in molecular biology from the University of Manchester, United Kingdom.

View Profile

Floriane Reinaud

Ms. Reinaud manages the PharmOnline International (POLI) and therapeutic module databases. She oversees the global information management team that manages the pharmaceutical pricing, cost and reimbursement data, including product positioning, client support, associated research and consulting projects. Ms. Reinaud is an authority on the impact of P&R policies, market access strategies and specialist topics, including risk-sharing agreements, orphan drugs, generics and biosimilars. She joined the company in 2007 and has over ten years of experience in pricing and reimbursement. Floriane Reinaud studied biology and holds an Master of Science in biochemistry, as well as Master of Science in healthcare marketing. She co-authored a peer-reviewed article that was published in The Journal of Biological Biochemistry. She is fluent in French and English.

View Profile

Timothy Dall

​A trained health economist, he brings more than 20 years of experience conducting research and policy analysis in the areas of health economics and outcomes, health workforce, health care delivery and disease cost and prevention. His work applies economic theory, statistical and econometric analysis, cost/benefit analysis, program evaluation, and computer modeling skills. Much of his work uses microsimulation modeling to address complex forecasting and policy issues. Applied research conducted by Mr. Dall supports strategic planning and advocacy work for governments, associations, life sciences companies, payers, provider networks, and non-profit organizations. He has published widely in peer-reviewed journals. Mr. Dall earned his Master of Science in Labor Economics at the University of Wisconsin-Madison, US, and his Bachelor of Science in Economics from Utah State University, Logan, Utah, US.

View Profile

Follow IHS Markit Life Sciences on Twitter

{}

Explore

Filter Sort